Efficacy and Safety of Alirocumab and Evolocumab as ProproteinConvertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in FamilialHypercholesterolemia: A Systematic Review and Meta-Analysis

Post time 7 day(s) ago

journal：Current Medicinal Chemistry

Authors：Ghasem Ghasempour; Fahimeh Zamani-Garmsiri; Farhad Shaikhnia; Ali Akbar Soleimani; Syed Reza Hosseini Fard; Janani Leila; Shohreh Teimuri; Najmeh Parvaz; Payam Mohammadi; Mohammad Najafi

Published date：2024-1-

DOI：10.2174/0929867330666230228120601

PDF link：https://www.eurekaselect.com/art ... 7330666230228120601

Article link：http://dx.doi.org/10.2174/0929867330666230228120601

Article Source：Bentham Science Publishers Ltd.。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 6 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Bentham] Efficacy and Safety of Alirocumab and Evolocumab as ProproteinConvertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in FamilialHypercholesterolemia: A Systematic Review and Meta-Analysis

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today